- Trials with a EudraCT protocol (574)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
574 result(s) found for: Brain death.
Displaying page 1 of 29.
EudraCT Number: 2008-001909-41 | Sponsor Protocol Number: 5070197 | Start Date*: 2008-04-11 | ||||||||||||||||||||||||||
Sponsor Name:Stepani Bendel | ||||||||||||||||||||||||||||
Full Title: Hydrokortisonihoito elinluovutuspotilailla (HYDRO) | ||||||||||||||||||||||||||||
Medical condition: Tutkittavilla on vakava aivovamma ja/tai lukinkalvonalainen verenvuoto, eikä heitä voida parantaa sairaudestaan. Heitä hoidetaan teho-osastolla mahdollisina elintenluovutuspotilaina. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FI (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-003618-18 | Sponsor Protocol Number: M10-897 | Start Date*: 2013-04-19 | |||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Su... | |||||||||||||
Medical condition: Brain metastases from NSCLC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) BE (Completed) CZ (Completed) FI (Completed) ES (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001879-20 | Sponsor Protocol Number: 38RC18.085 | Start Date*: 2018-07-30 | |||||||||||
Sponsor Name:Grenoble Alps University Hospital | |||||||||||||
Full Title: Radiotherapy of multiple brain metastases using AGuIX® gadolinium-chelated polysiloxane based nanoparticles: a prospective randomized phase II clinical trial. | |||||||||||||
Medical condition: Patients with brain metastases, from a histologically confirmed solid tumor, eligible for WBRT | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003669-14 | Sponsor Protocol Number: ISRCTN15088122 | Start Date*: 2012-12-03 | |||||||||||
Sponsor Name:London School Of Hygiene and Tropical Medicine | |||||||||||||
Full Title: Tranexamic Acid for the treatment of significant traumatic brain injury: an international, randomised, double blind, placebo controlled trial. | |||||||||||||
Medical condition: Traumatic Brain Injury | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GB (Completed) IT (Completed) IE (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002109-58 | Sponsor Protocol Number: RSR13 RT-016 | Start Date*: 2005-02-14 | |||||||||||
Sponsor Name:ALLOS Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Open-label Comparative Study of Standard Whole Brain Radiation Therapy with Supplemental Oxygen, with or without Concurrent RSR13 (efaproxiral), in Women with Brain Metastases... | |||||||||||||
Medical condition: Brain metastases from breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) HU (Completed) GB (Completed) LT (Completed) ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003391-40 | Sponsor Protocol Number: 2020-KEP-456 | Start Date*: 2020-12-17 | |||||||||||
Sponsor Name:London School of Hygiene and Tropical Medicine | |||||||||||||
Full Title: Intramuscular tranexamic acid for the treatment of symptomatic mild traumatic brain injury in older adults: a randomised, double-blind, placebo-controlled trial. | |||||||||||||
Medical condition: Mild traumatic brain injury. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006694-39 | Sponsor Protocol Number: ASF-CP02-001 | Start Date*: 2022-07-08 | ||||||||||||||||
Sponsor Name:Lantmännen Medical AB | ||||||||||||||||||
Full Title: An open-label, historical cohort control study to evaluate the safety and tolerability of AF-16 in patients with cerebral oedema caused by traumatic brain injury (TBI) | ||||||||||||||||||
Medical condition: Cerebral oedema caused by traumatic brain injury (TBI) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007350-35 | Sponsor Protocol Number: ML 22203 | Start Date*: 2009-07-17 | |||||||||||
Sponsor Name:ROCHE | |||||||||||||
Full Title: A single arm, open-label trial assessing the effect of Capecitabine (Xeloda®) on progression-free survival rate at four months in breast cancer patients with CNS progression after whole brain radio... | |||||||||||||
Medical condition: Female breast cancer patients with progression of brain metastasis following WBRT and at least one measurable lesion in the brain (defined as any lesion >1 cm in longest dimension at MRI). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005647-24 | Sponsor Protocol Number: MIA2019/CT/258 | Start Date*: 2021-05-10 | |||||||||||
Sponsor Name:Melanoma Institute Australia | |||||||||||||
Full Title: A phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with melanoma brain met... | |||||||||||||
Medical condition: melanoma brain metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Prematurely Ended) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003858-24 | Sponsor Protocol Number: 252BN201 | Start Date*: 2019-08-13 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Multicenter, Double-Blind, Multidose, Placebo-Controlled, Randomized, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 for Patients with Brain Contusion | |||||||||||||
Medical condition: Brain contusion | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005735-79 | Sponsor Protocol Number: UC-BCG-2011 | Start Date*: 2021-09-02 | |||||||||||||||||||||
Sponsor Name:UNICANCER | |||||||||||||||||||||||
Full Title: Treatment with Tucatinib in addition to Pertuzumab and Trastuzumab in patients with HER2-positive metastatic breast cancer after local therapy of isolated brain progression | |||||||||||||||||||||||
Medical condition: HER2-positive metastatic breast cancer with isolated brain progression (defined as new or progressive brain metastases with stable or responding systemic disease) after complete local treatment. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002845-39 | Sponsor Protocol Number: Infmed1 | Start Date*: 2019-10-02 | |||||||||||
Sponsor Name:Aalborg University Hospital | |||||||||||||
Full Title: Partial oral antibiotic treatment for bacterial brain abscess: An open-label randomised non-inferiority trial (ORAL) | |||||||||||||
Medical condition: Brain abscess | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000678-41 | Sponsor Protocol Number: ET19-006 | Start Date*: 2019-05-13 |
Sponsor Name:Centre Léon Bérard | ||
Full Title: CABRAMET - A phase 2 study of cabozantinib in renal cell carcinoma (mRCC) with brain metastases | ||
Medical condition: Metastatic renal cell carcinoma with non locally pre-treated brain metastases, in first line treatment or after one or two prior treatments. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2007-001768-60 | Sponsor Protocol Number: CNS 2007 04 | Start Date*: 2007-10-01 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: A Phase II Multi-Centre Study of Concomitant and Prolonged Adjuvant Temozolomide with Radiotherapy in Diffuse Pontine Gliomas | |||||||||||||
Medical condition: Diffuse pontine glioma in children | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001735-49 | Sponsor Protocol Number: CTU/2015/174 | Start Date*: 2019-07-01 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Rivaroxaban versus warfarin for stroke patients with antiphospholipid syndrome, with or without SLE (RISAPS): a randomised, controlled, open-label, phase II/III, non-inferiority trial | |||||||||||||
Medical condition: Patients with stroke or other ischaemic brain injury who have antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002185-23 | Sponsor Protocol Number: DIPG | Start Date*: 2015-07-29 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: Phase 2 open label randomized study of radiotherapy, concomitant nimotuzumab and vinorelbine and re-irradiation at relapse versus radiotherapy and multiple elective radiotherapy courses with concom... | |||||||||||||
Medical condition: diffuse intrinsic pontine glioma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000954-46 | Sponsor Protocol Number: MO25743 | Start Date*: 2011-09-26 | |||||||||||
Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||
Full Title: An open-label, single-arm, phase II, multicenter study to evaluate the efficacy of vemurafenib in metastatic melanoma patients with brain metastases | |||||||||||||
Medical condition: Metastatic Melanoma with Brain Metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003190-26 | Sponsor Protocol Number: RESTART13 | Start Date*: 2013-01-14 | |||||||||||
Sponsor Name:ACCORD (Academic and Clinical Central Office for Research & Development) [...] | |||||||||||||
Full Title: REstart or STop Antithrombotics Randomised Trial (RESTART) | |||||||||||||
Medical condition: Spontaneous Intracerebral Haemorrhage (ICH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019637-96 | Sponsor Protocol Number: YMB1000-018 | Start Date*: 2010-12-20 |
Sponsor Name:YMBiosciences INC | ||
Full Title: A Randomized, Phase II, Double-Blind Study of Nimotuzumab Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non-Small Cell Lung Cancer | ||
Medical condition: Brain metastases from Non-Small Cell Lung Cancer (NSCLC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005555-27 | Sponsor Protocol Number: ESR-14-10473 | Start Date*: 2017-09-12 |
Sponsor Name:University Hospital Basel | ||
Full Title: Prevention of Cerebral Ischaemia in Stent Treatment for Carotid Artery Stenosis - A randomised multi-centre phase II trial comparing Ticagrelor versus Clopidogrel with outcome assessment on MRI (PR... | ||
Medical condition: Carotid artery stenting (CAS) is treatment for atherosclerotic carotid stenosis. The main adverse events are thromboembolic brain infarcts during the procedure. Ticagrelor, a novel reversible inhib... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) BE (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
